Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates

Lee, Jung Heon; Yigit, Mehmet V.; Mazumdar, Debapriya; Lu, Yi

doi:10.1016/j.addr.2010.03.003

Cited by 269 publications

(149 citation statements)

References 187 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…Aptamers have some advantages over agents such as antibodies, including easier production, the potential for scaling up at a low cost, low batch-to-batch variability [121], selectivity for a wide range of targets [122], much greater stability (with respect to biological degradation, heat, pH and organic solvents) [122], transport at ambient temperatures and long-term storage [100], slow degradation kinetics, multiple denaturation and renaturation times without significant loss of activity [123], easy chemical modification with functional groups [121], lack of immunogenicity [121], smaller size (∼1-2 nm diameter, <10 kDa) and better tissue penetration in solid tumors [99,122].…”

Section: Aptamersmentioning

confidence: 99%

Oligonucleotide-Based Theranostic Nanoparticles in Cancer Therapy

Shahbazi

Özpolat

Ulubayram

2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Theranostic approaches, combining the functionality of both therapy and imaging, have shown potential in cancer nanomedicine. Oligonucleotides such as small interfering RNA and microRNA, which are powerful therapeutic agents, have been effectively employed in theranostic systems against various cancers. Nanoparticles are used to deliver oligonucleotides into tumors by passive or active targeting while protecting the oligonucleotides from nucleases in the extracellular environment. The use of quantum dots, iron oxide nanoparticles and gold nanoparticles and tagging with contrast agents, like fluorescent dyes, optical or magnetic agents and various radioisotopes, has facilitated early detection of tumors and evaluation of therapeutic efficacy. In this article, we review the advantages of theranostic applications in cancer therapy and imaging, with special attention to oligonucleotide-based therapeutics.

show abstract

Section: Aptamersmentioning

confidence: 99%

Oligonucleotide-Based Theranostic Nanoparticles in Cancer Therapy

Shahbazi

Özpolat

Ulubayram

2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…Regardless of composition, surface functionalization of the nanomaterial is required to enable targeting and stealth for long circulation times with minimal nonspecific binding [239]. There is a plethora of entities that can be incorporated onto a NP's surface, with covalent bonding preferred over electrostatic interactions: DNA, RNA, [472] oligonucleotides (aptamers), [29,434,[473][474][475][476] peptides, [36,175,201,[477][478][479][480][481][482] proteins, [483][484][485][486][487] enzymes, [488][489][490][491] antibodies [492]. No matter what the surface moiety, its activity must not be altered once anchored to the NP surface ( Figure 13).…”

Section: Functionalizationmentioning

confidence: 99%

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Trequesser¹,

Seznec²,

Delville³

2016

Nano Online

View full text Add to dashboard Cite

The successful development of nanomaterials illustrates the considerable interest in the development of new molecular probes for medical diagnosis and imaging. Substantial progress was made in synthesis protocol and characterization of these materials whereas toxicological issues are sometimes incomplete. Nanoparticle-based contrast agents tend to become efficient tools for enhancing medical diagnostics and surgery for a wide range of 2 imaging modalities. Multimodal nanoparticles (NPs) are much more efficient than conventional molecular-scale contrast agents. They provide new abilities for in vivo detection and enhanced targeting efficiencies through longer circulation times, designed clearance pathways, and multiple binding capacities. Properly protected, they can safely be used for the fabrication of various functional systems with targeting properties, reduced toxicity and proper removal from the body. This review mainly describes the advances in the development of mono-to multimodal NPs and their in vitro and in vivo relevant biomedical applications ranging from imaging and tracking to cancer treatment. Besides specific applications for classical imaging, (MRI, PET, CT, US, PAI) are also mentioned less common imaging techniques such as terahertz molecular imaging (THMI) or ion beam analysis (IBA).Perspectives on multimodal theranostic NPs and their potential for clinical advances are also mentioned.

show abstract

“…The next round of the selection process is usually performed under more stringent conditions (such as lower target concentration and shorter time for binding). After nearly 10-20 rounds of the selection processes, the nucleic acids with the highest affinity to the target molecule can be obtained [9][10][11]. The specific binding and high affinity constants of aptamers towards their substrates are comparable to the binding constants of antibodies to antigens.…”

Section: Electrochemical Aptasensorsmentioning

confidence: 99%

Aptasensors Based on Stripping Voltammetry

et al. 2016

Chemosensors

View full text Add to dashboard Cite

Aptasensors based on stripping voltammetry exhibit several advantages, such as high sensitivity and multi-target detection from stripping voltammetric technology, and high selectivity from the specific binding of apamers with targets. This review comprehensively discusses the recent accomplishments in signal amplification strategies based on nanomaterials, such as metal nanoparticles, semiconductor nanoparticles, and nanocomposite materials, which are detected by stripping voltammetry after suitable dissolution. Focus will be put in discussing multiple amplification strategies that are widely applied in aptasensors for small biomolecules, proteins, disease markers, and cancer cells.

show abstract

Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates

Cited by 269 publications

References 187 publications

Oligonucleotide-Based Theranostic Nanoparticles in Cancer Therapy

Oligonucleotide-Based Theranostic Nanoparticles in Cancer Therapy

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Aptasensors Based on Stripping Voltammetry

Contact Info

Product

Resources

About